A clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on our T-win technology platform. Our product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Lead Underwriter
Cowen and Company, LLC, Jefferies LLC, Morgan Stanley & Co. LLC
